1.Tunbridge WGM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG: The spectrum of thyroid disease in a community: The Whickham survey. Clin Endocrinol 7:481,1977.
1a. Studer H. Goiter from epiphenomenon of iodine deficiency to benign tumor. A 30-year long guided study. Schweiz Med Wochenschr 125:1379-1387,1995
2.Gharib TGH, Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidendtally on thyroid imaging. Ann Int Med 126:226-231,1997
3.Sawin CT, Bigos ST, Land S, Bacharach P.The aging thyroid. Relationship between elevated thyrotropin levels and thyroid antibodies in elderly patients. Am J Med 79:591,1985
4. Wang KW, Sum Cf, Tan KT, Ng WY,Cheah JS. A study of non-toxic goitre. Ann Acad Med Singapore 19:439-442,1990
5. Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. Am J Med 91:363-370,1991
6. Pinchera A, Aghini-Lombardi F, Antonangeli L, Vitti P. Multinodular goiter. Epidemiology and prevention. Ann Ital Chir 67:317-325,1996
8. Marine D: Etiology and prevention of simple goiter. Medicine 3:453,1924.
9. Taylor S: The evolution of nodular goiter. J Clin Endocrinol Metab 13:1232, 1953.
10. Beckers C, Cornette C: TSH production rate in nontoxic goiter. J Clin Endocrinol Metab 32:852,1971.
11. Dige-Petersen H, Hummer L: Serum thyrotropin concentrations under basal conditions and after stimulation with thyrotropin-releasing hormone in idiopathic non-toxic goiter. J Clin Endocrinol Metab 44:1115,1977.
12. Smeulers J, Docter R, Visser TJ, Hennemann G: Response to thyrotrophin-releasing hormone and triiodothyronine suppressibility in euthyroid multinodular goitre. Clin Endocrinology 7:389,1977.
12a. Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic non-toxic goiter. Am J Med 89:602-608,1995
13.Derwahl M, Studer H. Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Exp Clin Endocrinol Diabetes 109:250-60,2001
14. Studer H, Peter HJ, Gerber H: Natural heterogeneity of thyroid cells: The basis for understanding thyroid function and nodular growth. Endocr Rev 10:125,1989.
15. Peter HJ, Gerber H, Studer H, Smeds S: Pathogenesis of heterogeneity in human multinodular goiter. J Clin Invest 76:1992,1985.
16. Studer. H, Peter HJ, Gerber H. Natural heterogeneity of thyroid cells: The basis for understanding thyroid function and nodular goiter growth. End Rev 10:125-135,1998
16a. Kopp P, Kimura ET, Aeschimann S, et al. Polyclonal and monoclonal nodules coexist within human multinodular goiters. J Clin Endocrinol Metab 79:134-139,1994
16b. Peter HJ, Berber H, Studer H, Smeds S. Pathogenesis of heterogeneity in human multinodular goiter. J Clin Invest 76:1992,1985
16c. Holzapfel AP, Fuhrer D, Wonerow P, et al. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab 82:4292-4233,1997
16d. Tassi V, Di Cerbo A, Porcellini A, Papini E, Cisternino C, et al. Screening of thyrotropin receptor mutations by fine-needle aspiration biopsy in autonomous functioning thyroid nodules in multinodular goiters. Thyroid 9:353-357,1999.
16e. Gabriel EM, Bergert ER, Grant CS, van Heerden JA, Thompson GB, et al. Germline polymorphism of codon 727 of human thyroid-stimulating receptor is associated with toxic multinodular goiter. J Clin Endocrinol Metab 84:3328-3335,1999
16f. Neumann S, Willgerodt H, Ackermann F, Reske A, Jung M, Reis A, Paschke R. Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I- symporter. J Clin Endocrinol Metab 84:3750-3756,1999
17. Krohn K, Wohlgemuth S, Gerber H, Paschke R. Hot microscopic areas of iodine-deficient euthyroid goitres contain constitutively activating TSH receptor mutations. J Pathol 192:37-42,2000
17b. Knut Krohn, Dagmar Führer, Yvonne Bayer, Markus Eszlinger, Volker Brauer, Susanne Neumann and Ralf Paschke Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter. Endocr Rev. 2005 Jun;26(4):504-24.
18. Masini-Repiso AM, Cobanillas AM, Bonaventura M, Coleoni AH. Dissociation of thyrotropin-dependent enzyme activities, reduced iodide transport, and preserved iodide organification in nonfuntioning adenoma and multinodular goiter. J Clin Endocrinol Metab 79:39,1994.
18.a Dumont JE, Ermans AM, Maenhaut C, Coppee F, Stanbury JB. Large goitre as a maladaptation to iodine deficiency. Clin Endocrinol (Oxf). 1995 Jul;43(1):1-10.
19. Koutras DA, Alexander WD, Buchanan WW, Crooks J, Wayne JE: Stable iodine metabolism in non-toxic goitre. Lancet 2:784,1960.
20. Glinoer D, Lemone M. Goiter and pregnancy: A new insight into an old problem. Thyroid 2: 65,1992.
21. Baschieri L, Andreani D, Andreoli M, Negri M, Cassano C: Il ricambio dello iodio in gravidanza. Folia Endocrinol 12:3,1959.
22. Aboul-Khair SA, Crooks J, Turnbull AC, Hytten FE: The physiological changes in thyroid function during pregnancy. Clin Sci 27:195,1964.
23. Cassano C, Baschieri L, Andreani D: Etude de 48 cas de goitre simple avec élévation de la clearance rénale de l'iode, in Pitt-Rivers R (ed): Advances in Thyroid Research. Oxford, Pergamon Press, 1961,p 307.
24. Akerman M, DiPaola R, Tubiana M: Estimation of the absolute thyroid uptake of stable 127I using a simplified method and comparison of the results with two classic methods. J Clin Endocrinol Metab 27:1309,1967.
25. Vulsma T, Gons MH, de Vijlder JJM. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. New Engl J Med 321:13,1989.
27. Gaitan E: Goitrogens. Clin Endocrinol Metab 2:683,1988.
28. Peltola P: The role of L-5-vinyl-2-thiooxazolidone in the genesis of endemic goiter in Finland, in Cassano C, Andreoli M (eds): Current Topics in Thyroid Research. New York, Academic Press Inc, 1965,p 872.
29. Langer P: Antithyroid action in rats of small doses of some naturally occurring compounds. Endocrinology 79:1117,1966.
30. Langer P & Greer MA (eds). Antithyroid substances and naturally occurring goitrogens. 1977, S Karger. Basel.
31. Harden R McG, Alexander WD, Chisholm CJS, Shimmins J: The salivary iodide trap in nontoxic goiter. J Clin Endocrinol Metab 28:117,1968.
32. Parker RH, Beierwaltes WH: Inheritance of defective organification of iodine in familial goitrous cretinism. J Clin Endocrinol Metab 21:21,1961.
33. McGirr EM: Sporadic goiter due to dyshormonogenesis, in Astwood EB (ed): Clinical Endocrinology. New York, Grune & Stratton Inc, 1960, vol 1, p 133.
34. Niepomniszcze H, Altschuler N, Korob MH, Degrossi OJ: Iodide-peroxidase activity in human thyroid. I. Studies on non-toxic nodular goiter. Acta Endocrinol 62:192,1969.
35. Peter HJ, Studer H, Forster R, Gerber H: The pathogenesis of "hot" and "cold" follicles in multinodular goiters. J Clin Endocrinol Metab 55:941,1982.
36. Studer H: A fresh look at an old thyroid disease: Euthyroid and hyperthyroid nodular goiter. J Endocrinol Invest 5:156,1982.
37. Schürch M, Peter HJ, Gerber H, Studer H. Cold follicles in a multinodular human goiter arise partly from a failing iodide pump and partly from deficient iodine organification. J Clin Endocrinol Metab 71:1224,1990.
37a. Masini-Repiso AM, Cabanillas AM, Bonaterra M, Coleoni AH.Dissociation of thyrotropin-dependent enzyme activities, reduced iodide transport, and preserved iodide organification in nonfunctioning thyroid adenoma and multinodular goiter. J Clin Endocrinol Metab 79:39-44,1994
38. Ieiri T, Cochaux P, Targovnik HM, Suzuki M, Shimoda S-I et al. A 3'splice-site mutation in the thyroglobulin gene responsible for congenital goiter with hypothyroidism. J Clin Invest 88,1901,1991.
42. Cheng YL, Birman KD, Schaudies RP, Ahmann AJ, d' Avis J, Geelhoed GW, Wartofsky L: Effects of epidermal growth factor on thyroglobulin and adenosine 3',5'-monophosphate production by cultured human thyrocytes. J Clin Endocrinol Metab 69:771,1989.
43. Sugenoya A, Masuda H, Komatzu M, Jokojama S, Shimizu T, Fujimori M, Kobajashi S, Iida F. Adenomatous goitre: therapeutic strategy, postoperative outcome, and study of epidermal growth factor receptor. Brit J Surg 79:404,1992.
44. Maciel RM, Moses AC, Villone G, Tramontano D, Ingbar SH: Demonstration of the production and physiological role of insulin-like growth factor II in rat thyroid follicular cells in culture. J Clin Invest 82:1546,1988.
45. Phillips ID, Becks GP, Logan A, Wang JF, Smith C et al. Altered expression of insulin growth factor-1 (IGF-I) and IGF binding proteins during rat hyperplasia and involution. Growth Factors 10:207,1994.
46. Takahashi S-I, Conti M, Van Wyk JJ: Thyrotropin potentiation of insulin-like growth factor-I dependent deoxyribonucleic acid synthesis in FRTL-5 cells: Mediation by an autocrine amplification factor(s). Endocrinology 126:736,1990.
47. Vanelli GB, Barni T, Modigliani U, Paulin I, Serio M, Maggi M, Fiorelli G, Balboni GC. Insulin-like growth factor-I receptors in non-functioning thyroid nodules. J Clin Endocrinol Metab 71:1175,1990.
48. deVito WJ, Chanoine J-P, Alex S, Fang S-L, Stone S. Effect of in vivo administration of recombinant acidic fibroblast growth factor on thyroid function in the rat: induction of colloid goiter. Endocrinology 131:729,1992.
48a. Thompson SD, Franklyn JA, Watkinson JC, et al. Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. J Clin Endocrinol Metab 83:1336-1341,1998
48c. Francia FG, Azzolina L, Mantovani T, et al. Heterogeneity of nuclear DNA pattern and its relationship with cell cycle activity parameters in multinodular goiter. Clin Endocrinol 46:649-654,1997
48c. SP Bidey, DJ Hill, and MC Eggo Growth factors and goitrogenesis J Endocrinol 1999 160: 321-332.
49. Vagenakis AG, Wang CA, Burger A, Maloof F, Braverman LE, Ingbar SH: Iodide-induced thyrotoxicosis in Boston. N Engl J Med 287:523,1972.
50. Pelizzo MR, Piotto A, Rubello D, Casara D, Fassina A, Busnardo B. High prevalence of occult papillary thyroid carcinoma in a surgical series for benign thyroid disease. Tumori 76:255,1990.
51. McCall A, Jarosz H, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma in solitary cold nodules and in multinodular goiters. Surgery 100:1128,1986.
52. Koh KB, Chang KW. Carcinoma in multinodular goiter. Brit J Surg 79:266,1992.
53. Smeulers J, Docter R, Visser TJ, Hennemann G. Acute thyrotoxicosis in multinodular goiter. Neth J Med 20:275,1977.
54. Hamburger JI, Taylor CI. Transient thyrotoxicosis associated with acute hemorragic infarction of autonomously functioning thyroid nodules. Ann Intern Med 91:406,1979.
55. Plummer HS: The clinical and pathologic relationship of hyperplastic and nonhyperplastic goiters. JAMA 61:650,1913.
56. Elte JW, Bussemaker JK, Haak A. The natural history of euthyroid multinodular goiter. Postgrad Med J 66:186,1990.
57. Smeulers J, Visser TJ, Docter R, Hennemann G. Occasional thyroxine and triiodothyronine hypersecretion in euthyroid multinodular goiter. Neth J Med 23:152,1980.
58. Stoffer RP, Welch JW, Hellwig CA, Chesky VE, McCusker EN: Nodular goiter. Arch Intern Med 106:10,1960.
59. Sampson RJ, et al: Thyroid carcinoma in Hiroshima and Nagasaki. I. Prevalence of thyroid carcinoma at autopsy. JAMA 209:65,1969.
60. Sokal JE: A long term follow-up of non-toxic nodular goiter. Arch Intern Med 99:60,1957.
61. Sokal JE: The incidence of thyroid cancer and the problem of malignancy in nodular goiter, in Astwood EB (ed): Clinical Endocrinology. New York, Grune & Stratton Inc, 1960,, vol 1, p168.
62. Mustacchi P, Cutler SJ. Some observations on the incidence of thyroid cancer in the United States. N Engl J Med 255:889,1956.
63. Butler SJ, Young JL. Third national cancer survey incidence data, National Cancer Institute. Washington, DC: Dept. of Health, Education and Wellfare (NIH). p775,1975.
64. Riccabona OA. Thyroid cancer: its epidemiology, clinical features and treatment. Springer Verlag 1987.
65. Catler SJ, Scotto J, Devesa SS, Connally RR. Third National Cancer Survey - an overview of available information. J Natl Cancer Inst 53:1565,1974.
66. Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1.020 sequential autopsies. Am J Clin Pathol 90:72,1988.
67. Fukunaga FH, Lockett LJ: Thyroid carcinoma in the Japanese in Hawaii. Arch Pathol Lab Med 92:6,1971.
68. Sampson RJ, Key CR, Buncher CR, Iijima S: Smallest form of papillary carcinoma of the thyroid. Arch Pathol Lab Med 91:334,1971.
69. Sampson RJ, Woolner LB, Bahn RC, Kurland LT: Occult thyroid carcinoma in Olmsted County, Minnesota: Prevalence at autopsy compared with that in Hiroshima and Nagasaki. Jpn Cancer 34:2072,1974.
70. Harvey HK. Diagnosis and management of the thyroid nodule. Otolaryngol Clin N Am 23:303,1990
71. McConahey WM, Hay ID, Woolner LB, Van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61:978,1986.
72. Plummer HS: The function of the thyroid gland containing adenomatous tissue. Trans Assoc Am Physicians 43:159,1928.
73. Davis PJ, Davis FB: Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients. Medicine 53:161,1974.
74. Hamburger JI: Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab 50:1089,1980.
75. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Eng J Med 331:1249-1251,1994
76. Bonnema SJ, Bennedbaek FN, Wiersinga WM, Hegedus L. Management of the nontoxic multinodular goitre: a European questionaire study. Clin Endocrinol (Oxf) 53:5-12,2000
80. Hegedüs L, Hansen BM, Knudsen N, Hansen JM: Reduction of size of thyroid with radioactive iodine in multinodular nontoxic goitre. Brit Med J 297:661,1988.
81. Hamburger JI, Hamburger SW: Diagnosis and management of large toxic multinodular goiters. J Nucl Med 26:888,1985.
82. Kay TW, d'Emden MC, Andrews JT, Martin FI: Treatment of non-toxic multinodular goiter with radioactive iodine. Am J Med 84:19,1988.
84.Huysmans D, Hermus A, Edelbroek M, et al. Radioiodine for nontoxic multinodular goiter. Thyroid 7:235-239,1997
85. Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Soe-Jensen G et al. Radioiodine treatment of multinodular non-toxic goitre. Br Med J 307:828,1993.
86. Danaci M, Veek CM, Notghi A, Merck MV, Padfield PL, Edwards CR. 131I radioiodine therapy for hyperthyroidism in patients with Graves' disease, uninodular goiter and multinodular goiter. N Z Med J 101:784,1988.
86a. Nygaard B, Hegedus L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 159:1364-1368,1999
87. Aach R, Kissane J: Thyroid storm shortly after 131I therapy of a toxic multinodular goiter. Am J Med 52:786,1972.
87a. Huysmans AK, Hermus RM, Corstens FAM, Barents JO, Kloppenborgh PWC. Large compressive goiters treated with radioiodine. Ann Int Med 121:757,1994
87b. Nygaard B, Soes-Petersen U, Hoilund-Carlsen PF, et al. Improvement of upper airway obstruction after131-treatment of multinodular nontoxic goiter evaluated by flow volume loop curves. J Endocrinol Invest 19:71-75,1996
87c. Nygaard B, Faber J, Hegedus L. Acute changes in thyroid volume and function following131I therapy in multinodular goiter. Clin Endocrinol 41:715-718,1996
87d. Nygaard B, Hegedus L, Ulriksen P, Nielsen KG, Hansen Jm. Radioiodine therapy for multinodular goiter. Arch Intern Med 159:1364-1368,1999
87da. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, Schellekens AP, Bus JW, Bravenboer B, Hermus AR. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter.J Clin Endocrinol Metab 85:3592-6,2000
87dbNielsen VE, Bonnema SJ, Boel-Jorgensen H, Veje A, Hegedus L. .Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial J Clin Endocrinol Metab. 2005 Jan;90(1):79-83.
87e. Bergfelt G, Risholm L. Postoperative thyroid hormone therapy in nontoxic goiter. Act Chirg Scand 126:531, 1963
87f. Hegedus L, Hansen Jm, Veiergang D, Kastrup S. Does prophylactic thyroxine treatment after operation for nontoxic goitre influence thyroid size? Brit Med J 294:801,1987
87g. Berghout A, Wiersing Wm, Drexhage HA et al. The long-term outcome of thyroidectomy for sporadic nontoxic goiter. Clin Endocrinology 31:193,1989
87h. Geerdsen JP, Frölund L. Recurrence of nontoxic goitre with and without postoperative thyroxine medication. Clin Endocrinology 21:529,1984
88. Ermans AM, Camus M: Modifications of thyroid function induced by chronic administration of iodide in the presence of autonomous thyroid tissue. Acta Endocrinol 70:463,1972.
88a. Jensen Md, Charib H, Naessens JM, et al. Treatment of toxic multinodular goiter (Plummer’s Disease): surgery or radioiodine? World J Surgery 10,637-680, 1986
88b. Allahabadia A, Daykin J, Sheppard MC, Gough SLC, Kranklyn JA. Radioiodine treatment for hyperthyroidism - -prognostic figures for outcome. Procc.72nd Ann. Meeting ATA, 1999, abstr. no:62 p. 31
88c. Nygaard B, Faber J, Veje A, Hegedus L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy
88d. Huysmans AK, Hermus RM, Edelbroek MA, et al. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid 7:535-539,1997
88.1 Solymosi T, Gal I. Treatment of recurrent nodular goiters with percutaneous ethanol injection: A clinical study of twelve patients. Thyroid 13:273, 2003.
89. Gerber H, Studer H, Conti A, Engler H, Kohler H, Haeberli A: Reaccumulation of thyroglobulin and colloid in rat and mouse thyroid follicles during intense thyrotropin stimulation. A clue to the pathogenesis of colloid goiters. J Clin Invest 68:1338,1981.